New research from Emory University evaluated immune responses after the 2023–24 COVID vaccine. The study, published in Science and Translational Medicine, followed 24 participants for six months and measured memory B cells, binding antibodies, and neutralizing antibodies. The 2023–24 vaccine was monovalent and designed to match the then-dominant Omicron XBB.1.5 variant; previous vaccines had been bivalent.
Laboratory tests showed the vaccine produced antibodies with a half-life of more than 500 days, so at least half remained detectable more than 16 months after vaccination. Participants also produced cross-reactive antibodies that recognized both the ancestral WA1 strain and XBB.1.5. The researchers said immune imprinting likely contributed to a 2.8-fold increase in these cross-reactive antibodies.
The paper notes that SARS-CoV-2 has caused more than 1.2 million deaths nationwide and has many mutations. It also lists groups at higher risk of severe disease, such as people with cancer, autoimmune disorders, stroke, obesity, and existing heart, kidney, lung, or liver conditions.
Difficult words
- memory B cells — White blood cell that remembers past infections
- binding antibodies — Protein that binds to a virus or germ
- neutralizing antibodies — Antibody that can stop a virus infecting cells
- monovalent — Designed to target one strain or variant
- bivalent — Designed to target two different strains together
- half-life — Time for half of a substance to disappear
- immune imprinting — When first immune exposure shapes later responses
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Which of the risk groups named in the article would you put first for vaccine access in your community, and why?
- If antibodies remain detectable for many months, how might that change people’s plans for booster shots?
- How would you feel about a vaccine made to match a single dominant variant versus one that targets two variants? Explain briefly.
Related articles
Milk glands in many mammals have receptors for H5N1
A study found that milk gland tissue from pigs, sheep, goats, beef cattle, alpacas and humans contains sialic acid receptors that can let H5N1 attach to cells. Researchers warn of surveillance and concerns about raw milk from mammals.
Antibody and EGFR–STAT1 pathway point to new fibrosis treatments
Researchers at Yale found a human antibody that blocks epiregulin and lowers fibrosis markers. They also show EGFR activates STAT1 in fibroblasts, suggesting two treatment paths: block epiregulin or target the EGFR–STAT1 pathway.